Cited by 102Alzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis ResearchDementia and Cognitive Impairment Research

C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease

Open access
Harms, Matthew, Benitez, Bruno A., Cairns, Nigel, Cooper, Breanna, Cooper, Paul, Mayo, Kevin, Carrell, David, Faber, Kelley +11 more·2013·JAMA Neurology

Abstract

IMPORTANCE: Hexanucleotide repeat expansions in the chromosome 9 open reading frame 72 (C9orf72) gene underlie a significant fraction of frontotemporal dementia and amyotrophic lateral sclerosis. OBJECTIVE: To investigate the frequency of C9orf72 repeat expansions in clinically diagnosed late-onset Alzheimer disease (AD). DESIGN, SETTING, AND PATIENTS: This case-control study genotyped the C9orf72 repeat expansion in 872 unrelated familial AD cases and 888 control subjects recruited as part of the National Institute on Aging Late-Onset Alzheimer Disease Family Study cohort, a multisite collaboration studying 1000 families with 2 or more individuals clinically diagnosed as having late-onset AD. MAIN OUTCOMES AND MEASURES: We determined the presence or absence of the C9orf72 repeat expansion by repeat-primed polymerase chain reaction, the length of the longest nonexpanded allele, segregation of the genotype with disease, and clinical features of repeat expansion carriers. RESULTS Three families showed large C9orf72 hexanucleotide repeat expansions. Two additional families carried more than 30 repeats. Segregation with disease could be demonstrated in 3 families. One affected expansion carrier had neuropathology compatible with AD. In the National Institute on Aging Late-Onset Alzheimer Disease Family Study series, the C9orf72 repeat expansions constituted the second most common pathogenic mutation, just behind the PSEN1 A79V mutation, highlighting the heterogeneity of clinical presentations associated with repeat expansions. CONCLUSIONS AND RELEVANCE: C9orf72 repeat expansions explain a small proportion of patients with a clinical presentation indistinguishable from AD, and they highlight the necessity of screening frontotemporal dementia genes in clinical AD cases with strong family history.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/2013.jamaneurol.537

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • C9orf72 expansion mutations are associated with ALS/FTLD and also with symptoms reminiscent of Parkinson disease, Alzheimer disease, Huntington disease, and corticobasal syndrome.

    “For instance, C9orf72 expansion mutations are associated not only with ALS/FTLD, but also with symptoms reminiscent of Parkinson disease, Alzheimer disease, Huntington disease, and corticobasal syndrome, reinforcing the imperfect connection between clinical and molecular phenotypes and emphasizing the need for molecular diagnostics [155–164].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [16]Cruchaga C Chakraventy S Mayo K Vallania FL Mitra A Faber KM Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s Disease families PLoS One 2012 In Press. PMC3270040 22312439

Cited by

Sorted by citations

Authors
Harms, M., Benitez, B. A., Cairns, N., Cooper, B., Cooper, P., Mayo, K., Carrell, D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., Foroud, T. M., Boeve, B. F., Graff-Radford, N. R., Mayeux, R., Chakraverty, S., Goate, A. M., Cruchaga, C., & NIA-LOAD/NCRAD Family Study Consortium, F. T.
Affiliations
  • Washington University in St. Louis (US)
  • Indiana University Indianapolis (US)
  • Columbia University (US)
  • University of Washington (US)
  • The University of Texas Southwestern Medical Center (US)
  • Mayo Clinic (US)
Corresponding author
Cruchaga, Carlos
Venue
JAMA Neurology
Published
2013-06-01
Volume
70
Issue
6
Pages
736
ISSN
2168-6149 (ISSN-L)
OpenAlex
W2035247606
Cited by
102
References
33
Citations by year
2026: 1 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 7 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 10 · 2016: 8 · 2015: 9 · 2014: 19 · 2013: 11 · 2012: 1
FWCI
10.88
Type
journal article
Language
en
Open access
Locations
  • JAMA Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5p30ns069329-02)
  • National Institute on Aging (P50‐AG16574, U01AG06786, U01AG006786, R01 AG32306, R01AG035083, R01AG041797, P50AG008702, R01AG032306, P50AG005681, P30AG013846, P50AG005134, U24AG056270, U24AG021886, P30AG062421, P50AG016574)
  • National Institute of Mental Health (R01MH060009)
  • National Institute of Neurological Disorders and Stroke (P30-NS069329, K08NS075094)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
C9orf72, hexanucleotide repeat expansion, late-onset Alzheimer's disease, familial Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, genetic susceptibility, genetic screening, neuropathology
MeSH terms
C9orf72 Protein, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Pedigree, Proteins, Cohort Studies, Case-Control Studies, DNA Repeat Expansion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review